Cagrilintide (AM833): A Research Overview of the Long-Acting Amylin Analog

Cagrilintide is, by a wide margin, the most clinically advanced compound commonly grouped with research peptides. It is not a gray-market molecule with a thin file — it is a deliberately engineered drug candidate from Novo Nordisk, supported by peer-reviewed Phase 2 and Phase 3 trials and a published medicinal-chemistry and structural-biology record. That changes how it should be discussed: the task is less about flagging weak evidence and more about keeping two related-but-distinct things separate, and about not letting strong trial data slide into the false impression of an approved product.

This overview summarizes what the published literature reports on cagrilintide’s structure, mechanism, clinical evidence, and precise regulatory status. It describes findings as they appeared in their study populations. It is not dosing guidance, medical advice, or a recommendation for use.

What Cagrilintide Is

Cagrilintide (development codes AM833 / NN9838) is a synthetic, long-acting analog of amylin — a hormone co-secreted with insulin by pancreatic beta cells after meals that signals fullness, slows gastric emptying, and restrains glucagon release. Native amylin is useless as a chronic therapy because its half-life is measured in minutes. Cagrilintide was engineered to solve that: built on an amylin-based backbone with stabilizing substitutions and a fatty-acid acylation that enables reversible albumin binding, it achieves a half-life long enough for once-weekly subcutaneous dosing (medicinal chemistry of cagrilintide, J Med Chem 2021).

One distinction to keep clear throughout: cagrilintide is the standalone amylin analog. CagriSema is a separate, fixed-dose combination of cagrilintide plus the GLP-1 receptor agonist semaglutide. They have different trial data and regulatory standing, and popular coverage frequently blurs the lines between them. This article is about cagrilintide, and it flags which findings belong to the combination.

Mechanism of Action

Cagrilintide is described as a non-selective agonist — sometimes termed a dual amylin and calcitonin receptor agonist (DACRA). It activates the amylin receptor subtypes (AMY1, AMY2, AMY3), each a heterodimer of the calcitonin receptor core and a receptor-activity-modifying protein, as well as the calcitonin receptor itself (cagrilintide receptor structural biology, Nature Communications 2025). These receptors are concentrated in the brainstem and hypothalamic regions — the area postrema and nucleus tractus solitarius — that integrate satiety signals.

The downstream effect described in the research is reduced appetite, increased satiety, and slowed gastric emptying. Mechanistic work using amylin-receptor-knockout mice has gone further, reporting that cagrilintide lowers body weight specifically through brain amylin receptors 1 and 3 — an unusually direct identification of the responsible circuitry (cagrilintide and brain amylin receptors, eBioMedicine 2025). Conceptually, this matters because amylin signaling is a different pathway from the GLP-1 mechanism behind most current weight-management drugs, which is the rationale for studying the two together.

The Clinical Evidence Base

This is where cagrilintide separates itself from nearly everything else in this research space: the human data is substantial, peer-reviewed, and published in major journals.

Phase 2 monotherapy. A dose-finding Phase 2 trial published in The Lancet in 2021 tested once-weekly cagrilintide across a dose range in people with overweight and obesity. Cagrilintide monotherapy at its highest dose resulted in approximately 10.8% weight loss over 26 weeks, exceeding the active comparator in that study (Lau et al., Phase 2 dose-finding trial, referenced in Nat Commun). A more recent Phase 3 sub-analysis of cagrilintide monotherapy at 2.4 mg reported weight loss in the range of about 11.8% versus placebo (Lau et al., Phase 2 dose-finding trial, Lancet 2021).

Phase 3 combination (CagriSema). In the combination, the results are larger. The Phase 3 REDEFINE 1 trial — a 68-week, randomized, double-blind, placebo- and active-controlled study of 3,417 adults — evaluated CagriSema against its individual components and placebo, with reported weight loss for the combination in the low-20% range (REDEFINE 1, NEJM 2025). These are strong, controlled results — but they belong to the combination product, not to cagrilintide alone, and the distinction should not be lost.

Tolerability. Gastrointestinal effects are the most common reported adverse events for the amylin/GLP-1 approach — nausea, vomiting, and diarrhea — affecting a substantial share of recipients in combination trials, though most were characterized as mild to moderate and transient (safety/tolerability data, Lau et al., Lancet 2021).

Regulatory Status — Investigational, Not Approved

The status below reflects mid-2026 and is subject to change; verify against current FDA notices before relying on it. Cagrilintide is not FDA-approved for any indication. It is an investigational compound in active clinical development by Novo Nordisk, and it is not available through compounding pharmacies or by prescription outside of clinical trials (regulatory status overview).

The most current regulatory event concerns the combination, and precision matters here. In December 2025, Novo Nordisk submitted a New Drug Application to the FDA for CagriSema — the cagrilintide-plus-semaglutide combination — for chronic weight management, with review anticipated during 2026 (Novo Nordisk CagriSema NDA submission). Two clarifications follow. A submitted NDA is a request for review, not an approval; as of this writing, CagriSema is not approved in the US or EU. And the NDA is for the combination product, while cagrilintide monotherapy is being investigated separately (the dedicated Phase 3 RENEW program). In short: real, advanced, well-documented clinical development — but not, at this point, an approved medicine in any form.

Why Cagrilintide Draws Research Interest

The interest is straightforward and well-founded. Cagrilintide revives amylin — a satiety hormone that was clinically impractical because of its short half-life — as a once-weekly therapeutic, acting through a pathway distinct from the GLP-1 mechanism that dominates current obesity treatment. That distinct mechanism is exactly why it is studied both alone and alongside semaglutide, and the trial results to date have been substantial. The accurate framing is a genuinely promising, late-stage investigational therapy with strong published human data — not a finished, approved product, nor a research-chemical curiosity. It sits at the serious end of the spectrum.

For deeper reading, the primary literature cited throughout this article is the best starting point. Related amylin, calcitonin receptor, and metabolic therapy topics are collected in our peptide research library, which gathers reference material on the broader class of compounds discussed here.